Effective June 5, 2020, indinavir sulfate (Crixivan®) has been removed from the ADAP formulary. In March of 2020, ADAP received notification that the manufacturer of Crixivan®, an antiretroviral protease inhibitor, would cease production of the medication. The discontinuation is voluntary and not related to a safety, quality, or efficacy issue. As of May 2020, there is not a generic version of indinavir sulfate to maintain on the formulary; however, ADAP does have other protease inhibitors (e.g. atazanavir, darunavir, fosamprenavir, etc.) available through the formulary.
If you have any questions regarding the addition of these medications to the ADAP formulary, please contact Cynthia Reed-Aguayo, ADAP Specialist, at (916) 449-5791.
Sandra Robinson, MBA
ADAP Branch Chief
California Department of Public Health